sino biopharmaceutical ltd. - SBMFF

SBMFF

Close Chg Chg %
0.76 -0.06 -8.47%

Closed Market

0.70

-0.06 (8.47%)

Volume: 604.00

Last Updated:

May 4, 2026, 1:48 PM EDT

Company Overview: sino biopharmaceutical ltd. - SBMFF

SBMFF Key Data

Open

$0.74

Day Range

0.70 - 0.74

52 Week Range

0.49 - 1.24

Market Cap

$12.33B

Shares Outstanding

17.88B

Public Float

9.18B

Beta

0.43

Rev. Per Employee

N/A

P/E Ratio

38.18

EPS

$0.08

Yield

167.18%

Dividend

$0.01

EX-DIVIDEND DATE

Jun 26, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

135.73

 

SBMFF Performance

1 Week
 
-8.47%
 
1 Month
 
-16.15%
 
3 Months
 
-23.52%
 
1 Year
 
120.94%
 
5 Years
 
N/A
 

SBMFF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About sino biopharmaceutical ltd. - SBMFF

Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Investment, Modernised Chinese Medicines and Chemical Medicines; and Others. The Investment segment offers long-term investments. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long-term investments. The Other segment includes a research and development sector, which provides services to third parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse Cheung Ling Cheng and on February 2, 2000, and is headquartered in Hong Kong.

SBMFF At a Glance

Sino Biopharmaceutical Ltd.
Office Tower
Hong Kong,
Phone 852-2802-9886 Revenue 4.43B
Industry Pharmaceuticals: Major Net Income 325.99M
Sector Health Technology 2025 Sales Growth 10.411%
Fiscal Year-end 12 / 2026 Employees 21,435
View SEC Filings

SBMFF Valuation

P/E Current 38.18
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 43.867
Price to Sales Ratio 3.237
Price to Book Ratio 3.237
Price to Cash Flow Ratio 9.05
Enterprise Value to EBITDA 13.496
Enterprise Value to Sales 3.384
Total Debt to Enterprise Value 0.153

SBMFF Efficiency

Revenue/Employee 206,604.246
Income Per Employee 15,208.212
Receivables Turnover 3.821
Total Asset Turnover 0.446

SBMFF Liquidity

Current Ratio 1.368
Quick Ratio 1.278
Cash Ratio 0.911

SBMFF Profitability

Gross Margin 82.071
Operating Margin 21.352
Pretax Margin 22.286
Net Margin 7.361
Return on Assets 3.287
Return on Equity 7.436
Return on Total Capital 4.874
Return on Invested Capital 6.425

SBMFF Capital Structure

Total Debt to Total Equity 52.395
Total Debt to Total Capital 34.381
Total Debt to Total Assets 21.142
Long-Term Debt to Equity 24.946
Long-Term Debt to Total Capital 16.37
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sino Biopharmaceutical Ltd. - SBMFF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
4.27B 3.70B 4.01B 4.43B
Sales Growth
+2.62% -13.48% +8.47% +10.41%
Cost of Goods Sold (COGS) incl D&A
860.67M 704.28M 741.47M 794.02M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
149.67M 142.47M 179.64M 164.66M
Depreciation
134.57M 127.07M 155.38M 138.53M
Amortization of Intangibles
15.10M 15.40M 24.26M 26.13M
COGS Growth
+4.10% -18.17% +5.28% +7.09%
Gross Income
3.41B 2.99B 3.27B 3.63B
Gross Income Growth
+2.25% -12.30% +9.22% +11.17%
Gross Profit Margin
+79.86% +80.95% +81.51% +82.07%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.49B 2.18B 2.41B 2.69B
Research & Development
631.62M 621.45M 707.15M 816.07M
Other SG&A
1.86B 1.56B 1.70B 1.87B
SGA Growth
-1.93% -12.52% +10.42% +11.73%
Other Operating Expense
- - - -
-
Unusual Expense
62.35M 20.12M 177.60M 222.50M
EBIT after Unusual Expense
859.42M 793.88M 685.31M 723.08M
Non Operating Income/Expense
86.66M 113.79M 105.44M 302.61M
Non-Operating Interest Income
29.92M 26.35M 69.41M 88.14M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
65.20M 69.90M 41.01M 38.72M
Interest Expense Growth
+36.26% +7.20% -41.33% -5.58%
Gross Interest Expense
65.20M 69.90M 41.01M 38.72M
Interest Capitalized
- - - -
-
Pretax Income
880.88M 837.77M 749.74M 986.97M
Pretax Income Growth
+14.96% -4.89% -10.51% +31.64%
Pretax Margin
+20.61% +22.66% +18.69% +22.29%
Income Tax
115.24M 112.53M 68.49M 226.60M
Income Tax - Current - Domestic
115.49M 85.86M 136.41M 243.58M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(253.35K) 26.67M (67.92M) (16.98M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
742.92M 651.04M 664.81M 739.32M
Minority Interest Expense
365.18M 384.09M 398.07M 413.33M
Net Income
377.74M 266.95M 266.74M 325.99M
Net Income Growth
-83.32% -29.33% -0.08% +22.21%
Net Margin Growth
+8.84% +7.22% +6.65% +7.36%
Extraordinaries & Discontinued Operations
- - 62.19M (18.05M)
-
Discontinued Operations
- - 62.19M (18.05M)
-
Net Income After Extraordinaries
377.74M 329.14M 248.70M 325.99M
Preferred Dividends
- - - -
-
Net Income Available to Common
377.74M 329.14M 248.75M 325.99M
EPS (Basic)
0.0203 0.0178 0.0136 0.0181
EPS (Basic) Growth
-83.18% -12.32% -23.60% +33.09%
Basic Shares Outstanding
18.62B 18.53B 18.29B 18.00B
EPS (Diluted)
0.0199 0.0178 0.0136 0.0181
EPS (Diluted) Growth
-82.48% -10.55% -23.60% +33.09%
Diluted Shares Outstanding
19.02B 18.53B 18.30B 18.06B
EBITDA
1.07B 956.47M 1.04B 1.11B
EBITDA Growth
+12.99% -10.73% +9.00% +6.49%
EBITDA Margin
+25.07% +25.87% +25.99% +25.07%

Sino Biopharmaceutical Ltd. in the News